Compare FDP & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | ZLAB |
|---|---|---|
| Founded | 1886 | 2013 |
| Country | Cayman Islands | China |
| Employees | 39886 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1997 | 2017 |
| Metric | FDP | ZLAB |
|---|---|---|
| Price | $35.97 | $18.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $53.52 |
| AVG Volume (30 Days) | 307.3K | ★ 888.4K |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 413.60 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $4,316,000,000.00 | $441,629,000.00 |
| Revenue This Year | $1.82 | $26.16 |
| Revenue Next Year | N/A | $30.62 |
| P/E Ratio | $21.72 | ★ N/A |
| Revenue Growth | 0.94 | ★ 24.14 |
| 52 Week Low | $26.50 | $16.82 |
| 52 Week High | $40.75 | $44.34 |
| Indicator | FDP | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 47.64 |
| Support Level | $34.22 | $17.18 |
| Resistance Level | $35.74 | $19.32 |
| Average True Range (ATR) | 0.80 | 0.57 |
| MACD | -0.12 | 0.32 |
| Stochastic Oscillator | 39.06 | 63.08 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.